Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on Nov 12, 2024 8:02am
461 Views
Post# 36307878

First step of many big steps...

First step of many big steps...While we wait...(for the new people on this board).

In this link(paid advertising)....
.Pharma stock Theralase paves way for in-home cancer treatment | 2024-08-21 | Investing News | Stockhouse

It said...
'' Rutherrin has been shown to be effective across numerous potential applications, including:
-Bladder Cancer.
-Cancer Immunotherapy.
-Chemotherapy.
-Non-Small Cell Lung Cancer.
-Numerous Virus Including The Coronavirus.
Now the pharma stock(TLT) is solidifying these multi-billion-dollar addressable markets...Theralase also notes that because Rutherrin and Metformin both cross the blood-brain barrier,as well as tumour-specific blood barriers, their combination potentially allows Rutherrin to target
cancer cells anywhere in the body''

You can easily see that Ruvidar approval is just the very first step, of many multi-billion-dollard steps.


I love the short-term and long-term potential of TLT.


.
<< Previous
Bullboard Posts
Next >>